Abstract
Purpose :
The purpose of this study was to report clinical evidence for Faricimab in treating nAMD and its effectiveness in improving vision or reducing vision loss.
Methods :
This retrospective study included 139 eyes of 122 patients with nAMD. All patients were treated with Faricimab (6 mg in 0.05 mL) intravitreal injection (IVI) every 4 weeks for the first 4 doses. An ophthalmic evaluation was performed at the baseline and on every follow-up visit. The study included two groups: naive patients and patients previously treated with other anti-VEGF molecules, who showed features of suboptimal response to previous treatment.
The main outcomes were best-corrected visual acuity (BCVA) changes, and central retinal thickness (CRT) changes.
Results :
Of the 107 eyes previously treated with other anti-VEGF molecules, 55 eyes received the second IVI, the mean BCVA (LogMAR) before and after the first injection was 0.57 ± 0.32 and 0.49 ± 0.30 respectively (p-value < 0.05); The mean CRT (microns) was 381.90 ± 181.08 and 296.92 ± 132.32 respectively (p-value < 0.05). And 13 eyes received three IVIs, the mean BCVA (LogMAR) was 0.54 ± 0.22 at the baseline, 0.55 ± 0.25 after the first injection, and 0.52 ± 0.34 after the second injection (p-value > 0.05); The mean CRT was 393.61 ± 143.92 at the baseline, 319.23 ± 152.01 after the second injection, and 314.92 ± 143.92 after the third injection (p-value < 0.05).
Of the 32 naive eyes, 17 eyes received the second IVI, the mean BCVA (LogMAR) before and after the first injection was 0.46 ± 0.13 and 0.30 ± 0.17 respectively (p-value < 0.05); The mean CRT was 501.18 ± 215.72 and 321.94 ± 93.43 respectively (p-value < 0.05). And 6 eyes received three IVIs, the mean BCVA (LogMAR) was 0.52 ± 0.15 at the baseline, 0.37 ± 0.19 after the first injection, and 0.32 ± 0.15 after the second injection (p-value > 0.05); The mean CRT was 578.00 ± 311.51 at the baseline, 315.50 ± 57.22 after the second injection, and 293.00 ± 64.30 after the third injection (p-value > 0.05).
Both the mean BCVA and CRT improved in both naive and switched patients treated with Faricimab. No complications were reported in our study.
Conclusions :
Faricimab has shown promising results in its efficacy to improve both BCVA and CRT in patients with nAMD. However, this study shows early results. Thus, further research is needed to better evaluate the long-term efficacy and safety of this molecule.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.